Aptevo Therapeutics Stock Surges 4.17 as Trading Volume Spikes 82,774 Percent to Rank 433rd in Market Activity

On September 16, 2025, , . The stock ranked 433rd in trading activity among listed equities.

The significant spike in liquidity followed the company’s announcement of a strategic partnership to advance its lead oncology candidate, APV-112. The collaboration, which excludes financial terms, focuses on accelerating Phase II trial enrollment and expanding global manufacturing capacity. Analysts noted the deal’s potential to de-risk APV-112’s amid rising demand for novel cancer therapies.

Short-term momentum was further fueled by positive sentiment in the biotech sector, though APVO’s volume volatility remains an outlier. , with no material updates on clinical milestones or executive changes disclosed.

To run this back-test accurately I need a bit more detail: 1. Stock universe – which market or index should we draw the “top-500 by daily trading volume” from (e.g., all U.S. common stocks, S&P 500 constituents, Nasdaq only, etc.)? 2. Trading price – should the position open at the close of the ranking day and close at the next day’s close (close-to-close), or do you prefer another convention (e.g., next-day open to close)? 3. Transaction costs – do you want to assume zero costs, or should we include an estimate (commissions/slippage)? 4. Weighting – equal weight each stock, or volume-weighted / dollar-weighted? Once we lock these in, I can generate the data-retrieval plan and run the back-test.